title: Treating severe systemic lupus erythematosus with rituximab. An open study.
abstract: Systemic lupus erythematosus (SLE) is an autoimmune disease that may be associated to high morbidity and mortality. Disease course is variable and unpredictable and although the prognosis and survival of these patients has dramatically improved, treatment of severe multiorganic organic affection in this condition remains a therapeutic challenge. Since B lymphocytes have an important role in the pathogenesis of SLE, it is expected that the targeting of these cells exerts a significant therapeutic effect in SLE patients with severe multiorganic manifestations. In an open clinical trial, we have explored the therapeutic potential of Rituximab (an anti-CD20 monoclonal antibody) administration in SLE patients with severe nephritis (n=22) or neuropsychiatric manifestations (n=6) or massive pulmonary hemorrhage (n=3). In most cases, we observed significant improvement in both clinical and laboratory parameters, with good tolerance and few side effects. Thus, patients with severe lupus nephritis showed improvement in disease activity (MEX-SLEDAI index) with a significant reduction (p<0.05), as well as proteinuria in most of them (from 3.710g/L to 1.786g/L, p<0.05); patients with serious neurologic involvement had complete remission of their manifestations; but those with pulmonary massive hemorrhage did not have any response. Rituximab could have an important therapeutic potential in severe SLE, and that it is necessary to carry out a controlled blinded clinical trial to further support this point.
authors.affiliation: Regional Unit of Rheumatology and Osteoporosis, Facultad de Medicina y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, S.L.P., México.
authors.forename: Carlos
authors.initials: C
authors.lastname: Abud-Mendoza
authors.forename: Ricardo
authors.initials: R
authors.lastname: Moreno-Valdés
authors.forename: Enrique
authors.initials: E
authors.lastname: Cuevas-Orta
authors.forename: Antonio
authors.initials: A
authors.lastname: Borjas
authors.forename: Francisco
authors.initials: F
authors.lastname: Aranda
authors.forename: Fedra
authors.initials: F
authors.lastname: Irazoque
authors.forename: Lilia
authors.initials: L
authors.lastname: Andrade
authors.forename: M
authors.initials: M
authors.lastname: Vigna-Pérez
authors.forename: R
authors.initials: R
authors.lastname: González-Amaro